Pharmaceutical enterprise credit rating officially issued the breach of trust direct bidding hanging network, supply and distribution!

On July 24, the official website of the State Administration of Health Insurance officially issued the "Guidance on the Establishment of Drug Price stake and Credit Evaluation System for Recruitment (Draft for Comments)" for public consultation.
after two months of consultation with the community, this impact on all pharmaceutical companies, the bulk of the document, finally in the form of formal consultation with the National Health Insurance Administration to the public.
the policy relies on the bidding and procurement platform for pharmaceutical and medical supplies, system integration and trustworthiness commitment, credit rating, graded disposal, credit repair and other mechanisms, the establishment of equal rights and responsibilities, coordination of linked pharmaceutical prices and credit evaluation system.
, which aims to obtain improper benefits through the breach of trust listed in the catalogue list, shall be included in the scope of pharmaceutical price and credit evaluation for recruitment in the process of pricing, bidding, performance and marketing.
seven major breach of trust matters The State Administration of Health Insurance has established a list of medical prices and breach of trust matters, and the list of breach of trust includes, but not limited to, commercial bribery of pharmaceuticals, abuse of market dominance, tax-related violations, improper price behavior, malicious breach of contract agreements, and disturbing the centralized procurement order.
specifically, there are the following seven kinds of list included in the list of breach of trust: 1, the purchase and sale of medicines, to all kinds of medical institutions at all levels, centralized procurement agencies and their staff to give kickbacks or other improper benefits.
2, the implementation of monopoly agreements, abuse of market dominance, etc. are punished according to law, do not take the initiative to correct the unfair high prices of the products involved.
3, non-good-faith to obtain false VAT invoices.
4, fabricating, spreading information about price increases, raising prices, pushing prices to rise too high, and other violations of the Price Law.
5. Pharmaceutical enterprises shall be consulted, investigated, interviewed, admonished, inspected, pushed, refused, unable to fully explain the reasons or make false promises by the competent department of pharmaceutical prices for improper price behavior.
6, refuse to fulfill the promise without justifiable reasons, refuse to perform the purchase, sale or distribution contract.
7, bid on below-cost bids, bid sway, bid fraudulently, bid rigging, abuse of market dominance, etc., and disrupt the centralized procurement order.
, the document emphasizes that: from the date of the issuance of this opinion, pharmaceutical enterprises (including pharmaceutical production license holders, pharmaceutical and medical supplies production enterprises, distribution enterprises with the production enterprises with entrusted agent relations, as well as distribution enterprises, the same below) in the pricing, bidding, performance, marketing and other processes, through the list of list of breach of trust to obtain improper benefits, included in the scope of pharmaceutical prices and credit evaluation.
that is, from the date of the publication of the opinion, the document has been effective, that is, all pharmaceutical companies, there are bribes, kickbacks, false VAT invoices and other acts of breach of trust, are included in the scope of pharmaceutical prices and credit evaluation.
rating of joint and several liability breach escants for agents and employees? The content of the credit evaluation rating of the breach of trust behavior in the first two editions, from the conduct involved to the disciplinary measures, is not very detailed, the evaluation and punishment methods are almost dead end.
in this official public document, there is no overly detailed provisions, but only confirmed the four levels of breach of trust.
give situ at the same time to the local exploration of quantitative scoring space.
after all, this system involves collection, networking, record procurement and other recruitment behavior in the provinces and cities to complete, to the local health insurance bureau or recruitment departmentto to implement more appropriate.
"in accordance with the "reliable source, clear conditions, strict procedures, strict operation" requirements of the implementation of credit rating, according to the nature of the breach of trust, circumstances, timeliness, and the scope of impact and other factors, the pharmaceutical enterprises in the local tender procurement market of the breach of trust as general, medium, serious, especially serious four levels, dynamic updates on a quarterly basis.
the facts on which the credit rating is based on any breach of trust involving illegal and illegal acts shall be governed by the court's decision or the administrative punishment decision of the law enforcement department.
encourage local governments to explore quantitative credit rating methods to improve the standardization of credit rating.
" pharmaceutical field receiving rebates, monopoly control and sales and other acts resulting in the price of drugs and medical supplies inflated, medical expenses too fast growth, a large number of losses of medical insurance funds, seriously endangering the safety of medical insurance funds.
, the national level has also intensively issued regulations and policies against medical corruption.
recently, the National Health and Care Commission issued "on the issuance of the 2020 medical industry style construction work special action program notice", focusing on the treatment of medical personnel to collect rebates, pharmaceutical companies illegal marketing behavior.
can be seen, the idea of governance is very clear, from medical personnel and pharmaceutical companies at both ends of the crackdown, focus on the treatment of pharmaceutical bribery, regulate the marketing of pharmaceutical companies.
.